INTRODUCTION
Immunotherapy has revolutionized cancer therapy (Chen and Mellman, 2017) . Immune checkpoint protein inhibitors, such as antibodies against PD-L1 (aka CD274) and PD-1 (aka PDCD1), have shown effectiveness against a large number of cancer types, including melanoma, non-small-cell lung cancer, and renal cancer. This response includes durable remissions in many patients who had previously failed multiple other therapeutic strategies. However, even in these cancers, only 10%-30% of patients respond to anti-PD-L1/PD-1 therapy (Page et al., 2014) . In other cancers, such as prostate cancer, responses are rare (Goswami et al., 2016; Sharma et al., 2017) . The basis of differential therapeutic success between patients and between cancers remains largely unknown.
PD-L1 is a membrane bound ligand found on the cell surface of many cell types that is upregulated in the setting of inflammation and/or a number of oncogenic lesions (Topalian et al., 2015) . It binds the PD-1 receptor on immune T cells, leading to Sh2pdriven dephosphorylation of the T cell receptor and its co-receptor CD28, thereby suppressing antigen-driven activation of T cells (Hui et al., 2017; Yokosuka et al., 2012) . This mechanism normally keeps inflammatory responses in check, and Pd-l1 knockout mice develop autoimmune-like diseases (Francisco et al., 2010) . However, tumor cells can co-opt this mechanism to evade immune destruction. Therapeutic antibodies to PD-L1 and PD-1 block this interaction, which can then reactivate the anti-tumor immune response (Chen and Mellman, 2017) .
It is generally thought that PD-L1 functions within the tumor bed, where cell-surface PD-L1 is directly interacting with PD-1 on the surface of tumor-infiltrating lymphocytes (TILs) (Mellman et al., 2011) . However, PD-L1 also can be found on surface of extracellular vesicles (EVs). Furthermore, EV PD-L1 levels have been associated with tumor progression (Chen et al., 2018; Ricklefs et al., 2018; Theodoraki et al., 2018; Yang et al., 2018) . Whether extracellular PD-L1 can promote tumor progression by inducing a local and/or systemic immunosuppression is unknown.
EVs are heterogeneous (Tkach et al., 2018) . A particular form of EVs is exosomes, which derive from the endocytic pathway (van Niel et al., 2018) . As endosomes mature, vesicles bud inward and are released in the lumen forming intravesicular bodies within the late endosomes. These late endosomes are also called multivesicular bodies (MVB). MVBs can either fuse with lysosomes for degradation and recycling of contents or fuse with the plasma membrane releasing the intravesicular bodies extracellularly, which are then called exosomes. Exosomes can be differentiated from other EVs based on their size, morphology, density, marker expression, and dependency for specific enzymes for their biogenesis. Key enzymes in their biogenesis include NSMASE2 (aka SMPD3), which promotes budding of intravesicular vesicles, and RAB27A, which is involved in the fusion of the MVB to the plasma membrane (Kosaka et al., 2010; Ostrowski et al., 2010) . Genetic manipulation of these enzymes provides an opportunity to dissect the role of exosomes in vivo.
While evaluating mechanisms regulating levels of PD-L1 in different tumors, we discovered that cancer cells can secrete a vast majority of their PD-L1 on exosomes rather than present PD-L1 on their cell surface. Using genetic knockouts for Rab27a and nSMase2 and exogenously introduced exosomes, we show that exosomal PD-L1 from tumor cells promote tumor growth in an immune-dependent fashion. Exosomal PD-L1 suppresses T cell function in vitro and in vivo at the site of the draining lymph node. Exosomal PD-L1 appears to be resistant to anti-PD-L1 as a prostate cancer syngeneic model that is unresponsive to such therapy, is dependent on both PD-L1 and exosomes for their growth. Remarkably, even the transient presence of cancer cells deficient in exosomal PD-L1 results in long-term, systemic immunity against the cancer. A role for exosomal PD-L1 is also seen in a syngeneic colorectal model. In this model, anti-PD-L1 acts additively, not redundantly, with the suppression of PD-L1 secretion. These findings have significant implications for immunotherapeutic approaches to cancer therapy.
RESULTS

Differential Secretion of PD-L1 between Cancer Cell Lines
It has been reported that surface PD-L1 levels are low in prostate cancer cell lines and primary prostate tumor tissue, potentially explaining the general lack of therapeutic response to anti-PD-L1 blockade (Martin et al., 2015; Zang et al., 2007) . We sought to determine whether a transcriptional, post-transcriptional, translational, or post-translational mechanism underlies the reduced levels by comparing prostate cancer cell lines (PC3, DU145, LNCaP) to a melanoma cell line (SK-MEL-28). Measurements of mRNA and protein levels showed discordance between mRNA and protein levels across the different cancer cell lines. qRT-PCR showed a 15-fold increase of Pd-l1 mRNA levels in PC3 and DU145 relative to SK-MEL-28; LNCaP showed a near absence of transcripts ( Figure 1A) . In contrast to mRNA levels, western analysis showed similar cellular PD-L1 protein levels in PC3 and DU145 cells as SK-MEL-28 ( Figure 1B) ; protein was undetectable in LNCaP cells. We asked whether the discordance in mRNA and protein levels between PC3 and SK-MEL-28 could be explained by differences in protein translation. Translation rates were determined by polysome profiling, a method by which transcripts bound by many ribosomes reflective of a high translation rate are separated from transcripts bound by one or a few ribosomes reflective of a low translation rate (Chassé et al., 2017) . The two populations were separated on a sucrose gradient, and then the bound mRNA was measured by qRT-PCR ( Figure S1A ). This analysis showed an equal distribution of the Pd-l1 RNA across the fractions in PC3 and SK-MEL-28 (Figure S1B) . Thus, differences in translation rates cannot explain the discordance between mRNA and protein levels between the lines.
Next, we evaluated potential differences in protein degradation. The two main pathways for protein degradation are the lysosome and the proteasome (Ciechanover, 2005) . The small molecule Bafilomycin A1 (BafA1) inhibits lysosomal activity by blocking the V-ATPase hydrogen pump and thus acidification of the lysosome (Mauvezin and Neufeld, 2015) . An increase in the protein LC3B, a known target of the lysosome, confirmed effectiveness of the small molecule on PC3 and SK-MEL-28 cells. However, levels of PD-L1 in both lines were unaltered, implying little turnover of PD-L1 by the lysosome in these cells (Figures S1C and S1D). The small molecule MG132 suppresses proteasome activity by blocking the 26S proteasome complex and, consequentially, proteolysis (Lee and Goldberg, 1998) . The proteasome recognizes ubiquitin side chains on its targets (Lee and Goldberg, 1998 ). An increase in the presence of ubiquitinated proteins confirmed the effectiveness of MG132 on the two cells lines. Again though, PD-L1 protein levels were minimally affected, and, if anything, the difference of the two lines was opposite from expected as PD-L1 levels were slightly up in SK-MEL-28, but not in PC3, cells (Figures S2E and S2F) . These results show that differences in protein stability do not explain the discordance in mRNA and protein levels.
Next, we considered the possibility that PD-L1 may be differentially secreted from cells in the form of membrane vesicles. Extracellular vesicles can be enriched using sequential centrifugation transferring supernatant through increasing gravitational forces to remove cellular debris and apoptotic bodies, before finally pelleting at 100,000 gravitational forces (100k g) (Xu et al., 2016) . Western analysis showed 2-to 3-fold more PD-L1 in the 100k g fraction of PC3 cells relative to SK-MEL-28 cells ( Figure 1C ). This difference could have been due to more PD-L1 being loaded per vesicle or release of more vesicles. A nanoparticle tracking instrument can track the size and number of vesicles by using light diffraction off particles moving under Brownian motion (Carr and Warren, 2012) . Analysis of conditioned media from the two cell types showed a slightly elevated total vesicle count in SK-MEL-28 ( Figure 1D ). Thus, even though PC3 and SK-MEL-28 cells had similar levels of cellular PD-L1 protein, PC3 cells packaged greater amounts of PD-L1 into extracellular vesicles. This difference appears to underlie the discordance between mRNA and protein levels between the two cell lines.
In vivo, tumor cells can mediate adaptive resistance by upregulating PD-L1 in response to interferon-gamma (IFNg) released by the cytotoxic T lymphocytes within the tumor bed (Garcia-Diaz et al., 2017) . Therefore, we asked whether, in addition to upregulating cellular PD-L1, IFNg may increase the secretion of PD-L1. Treatment of cancer cells with IFNg led to an increase in PD-L1 in both the cellular and 100k g fractions ( Figure S2A ). The increase was proportionally similar between the two fractions, suggesting no direct impact of IFNg on PD-L1 secretion ( Figure S2B ). In addition, IFNg did not increase the number of vesicles secreted ( Figure S2C ). Thus, similar to the cell-surface membrane PD-L1, extracellular vesicular PD-L1 increases in response to IFNg.
PD-L1 Is Specifically Secreted within Exosomes
Extracellular vesicles come in multiple forms differing in size, density, protein markers, and biogenesis (Xu et al., 2016) . Given that PD-L1 is endocytosed from the surface of cells (Burr et al., 2017; Mezzadra et al., 2017) , we hypothesized that PD-L1 is being specifically secreted in the form of exosomes. Exosomes can be enriched relative to other vesicles based on their density by spinning the crude 100k g pellet on a sucrose gradient (Shurtleff et al., 2016) . The exosomal marker CD63 traveled in the 20%-40% sucrose fractions ( Figure 1E ). PD-L1 and the additional exosomal marker HRS colocalized with CD63 ( Figure 1F ). These data support that PD-L1 is packaged in exosomes.
Next, to determine if PD-L1 is specifically found in exosomes, we took a genetic approach to remove exosomes. We focused on the Rab27a and nSMase2 genes using CRISPR/Cas9- Figure 1 . Differential Secretion of PD-L1 in PC3 versus SK-MEL-28 Cells (A) qRT-PCR of Pd-l1 mRNA levels in one melanoma cell line (SK-MEL-28) and three prostate cancer cell lines (LNCAP, PC3, and DU145). n = 3. (B) Western analysis of cellular levels of PD-L1 in the same cells as (A) . Top: Representative western blot. Bottom: Quantification of three independent western blots. (C) Top left: Schematic for crude isolation of secreted vesicles by sequential centrifugation of media through increasing centrifugal forces and finally pelleted at 100k g. Bottom left: Representative western blot of PD-L1 in cells versus secreted vesicles of either PC3 or SK-MEL-28 cells. Right: Quantification. n = 6. (D) Nanoparticle tracking of size and quantity of secreted vesicles produced by PC3 and SK-MEL-28 cells. Left: Density plot for size. Right: Total vesicle number based on integration under the curve. n = 9. (E) Schematic of steps involved in exosome purification including sequential centrifugations of supernatant at increasing gravitation force and then 100k g pellet run on sucrose gradient. Location of exosomes is followed by a western blot for CD63. mediated mutagenesis to knock them out in PC3 cells ( Figures S3A-S3C ). Deletion of these two genes did not affect the proliferation of PC3 cells (Figures S3D and S3E) . To follow exosomes, we ectopically expressed CD63-GFP in the three genetic backgrounds. Measurement of the conditioned media showed an almost complete absence of CD63-GFP+ particles arising from the two mutant lines versus wild-type (WT) (Figure 2A ). To further evaluate the effect of the Rab27a and nSMase2 deletion on exosomes, we performed electron microscopy on sucrose gradient concentrated particles. The resultant images showed very few exosome-like particles in the Rab27a and nSMase2 null samples, with a greater loss in the Rab27a null cells ( Figures 2B-2dD ). Consistent with these images, western analysis showed an absence of endogenous CD63 in the 100k g preps from Rab27a null cells and a small amount remaining in the nSMase2 null cells ( Figure 2E ). In contrast to CD63 levels, nSMase2 showed a complete absence, while Rab27a null cells showed a dramatic reduction in PD-L1 in the 100k g fraction ( Figure 2E) . This difference appears to be due to an additional role for NSMASE2 on Pd-l1 transcription ( Figures S3F and S3G ).
Together, these data show critical roles for both Rab27a and nSMase2 in exosome biogenesis and PD-L1 secretion.
Given that PD-L1 is a trans-membrane protein, exosomal PD-L1 must arise from the limiting membrane of the late endosome. The limiting membrane of the late endosome initially arises from the endocytosis of the plasma membrane. However, material provided directly from the ER and Golgi as well as cytoplasm is added as the resultant endosome matures (van Niel et al., 2018) . Flow cytometry and immunofluorescence showed the presence of PD-L1 on both the surface and within vesicle-like structures inside PC3 cells ( Figures S4A and S4B ). Using standard cell fractionation techniques, PD-L1 and CD63 co-localized in the sucrose light, or endolysosomal fraction (Shurtleff et al., 2016 ) ( Figure S4C ). To determine whether exosomal PD-L1 directly arises from the ER or early Golgi, we took advantage of the fact that PD-L1 is glycosylated . This glycosylation was easily removed with the amidase PNGaseF, consistent with it being a N-linked oligosaccharide chain ( Figure S4D ). In contrast, the majority of cellular and all the exosomal PD-L1 was resistant to EndoH cleavage, consistent with maturation of the oligosaccharide chain in the distal Golgi (Stanley, 2011) . Therefore, exosomal PD-L1 does not appear to come directly from the ER or early Golgi. To measure the plasma membrane as a source, we performed a cellsurface biotinylation assay ( Figure S4E ). Biotin-labeled PD-L1 was found in the cells and exosomes of treated cells, showing that exosomal PD-L1 originates from the surface of the PC3 cells.
Exosomal PD-L1 Suppresses T Cell Activation In Vitro Next, we asked whether exosomal PD-L1 could function similarly to cell-surface PD-L1 in the suppression of T cell activation. PD-L1 function can be measured in vitro in the setting of Raji B cell presentation of antigen to Jurkat T cells (Hui et al., 2017) . Normally, this presentation would activate T cells, which can be measured by secretion of interleukin-2 (IL-2). However, if PD-L1 is exogenously expressed in the Raji B cells and PD-1 is exogenously expressed in the Jurkat T cells, T cell activation is suppressed (Hui et al., 2017) . In this setting, we asked whether exosomal PD-L1 from PC3 cells could replace exogenous expression of PD-L1 on the Raji B cells ( Figure 2G ). As expected, in the absence of exogenous expression of PD-L1 in Raji B cells, IL-2 secretion was high ( Figure 2H , compare first two bars). However, the introduction of the PC3 100k g extracellular fraction rerepressed IL-2 secretion showing that PC3 vesicles can replace Raji cell PD-L1 expression ( Figure 2H , third bar). To determine whether exosomal PD-L1 was responsible for this effect, we used CRISPR/Cas9 editing to delete the Pd-l1 gene in the PC3 cells ( Figure S4F ). Deletion of the Pd-l1 gene did not affect the proliferation of the PC3 cells or alter the number of vesicles released ( Figures S4G and S4H ). However, introduction of the Pd-l1 null PC3 100k g extracellular fraction failed to repress IL2 secretion ( Figure 2H , fourth bar). These data show that exosomal PD-L1 does function to suppress T cell activation in vitro.
Exosomal PD-L1 Promotes Tumor Progression
Given its ability to suppress T cell activation in vitro, we wanted to know whether exosomal PD-L1 can function in vivo to promote tumor progression. To do so, we turned to a syngeneic model of prostate cancer, the TRAMP-C2 model (Foster et al., 1997 ). This preclinical model, like human prostate cancer, is resistant to anti-PD-L1 blockade (Yu et al., 2012) . CRISPR/ Cas9-mediated deletion of Rab27a ( Figure S5A ) and Pd-l1 (Figure S5B) resulted in a loss of PD-L1 in the EV fraction ( Figure 3A ).
Loss of Rab27a did not influence cell-surface PD-L1 levels, nor did loss of Pd-l1 influence exosome production (Figures S5C and S5D) . Like with the PC3 cells, deletion of Rab27a or Pd-l1 did not affect the proliferation of the cells ( Figures 3B and 3C ). The WT, Rab27a null, and Pd-l1 null TRAMP-C2 cells were injected into the flanks of C57BL6/J syngeneic mice and were followed for over 4 months. All mice injected with the WT TRAMP-C2 cells had visible tumors by around 35 days and had to be euthanized between 40 and 71 days (Figures 3D and 3E) . In contrast, all mice injected with Rab27a null or Pd-l1 null TRAMP-C2 cells showed no tumor growth during the same time period ( Figure 3D) . Similarly, the mice injected with Rab27a and Pd-l1 null TRAMP-C2 cells showed a dramatically extended lifespan relative to their WT counterparts ( Figure 3E ). Indeed, a majority of the mice remained alive after 90 days, at which point they were used for the memory experiments described below.
To further confirm that the loss of Rab27a was blocking tumor growth through its role in exosome biogenesis, we repeated the experiments using nSMase2 null cells. nSMase2 was deleted again using CRISPR/Cas9-mediated mutagenesis ( Figure S5E ). Similar to PC3, nSMase2 null TRAMP-C2 cells showed a decrease in both cellular and extracellular levels of PD-L1 ( (D) Tumor growth volume over time following subcutaneous injection of 1 3 10 6 WT, Rab27a null, or Pd-l1 null TRAMP-C2 cells into immunocompetent B6 mice. n = 5 for each genotype. Error bars represent SEM. Tramp WT versus TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 Pd-l1 null, p < 0.0001. Tramp WT versus TRAMP-C2 nSMase2 null, p < 0.001 (twoway ANOVA test). (E) Mouse survival curve following injection of cells like in (D) . n = 10 for each genotype. Tramp WT versus TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 Pd-l1 null, p < 0.001. Tramp WT versus TRAMP-C2 nSMase2 null, p < 0.001 (log rank test). (F) Mouse survival curve following NOD-SCID IL2rg À/À (NSG) mice injected with 1 3 10 6 WT, Rab27a null, and Pd-l1 null TRAMP-C2 cells. n = 10 for Pd-l1 null and WT genotypes, n = 8 for Rab27a null genotype, n = 5 for nSMase2 null genotype. See also Figure S5 . and compared to their WT counterparts. Similar to Rab27a null TRAMP-C2 cells, the nSMase2 null TRAMP-C2 cells failed to form palpable tumors during the time period when mice receiving WT cells had to be euthanized ( Figure 3D ). Again, a majority of the mice (8 of 10) were still alive after 90 days (Figure S3E ). Together, these data show that blocking exosome biogenesis or removing PD-L1 result in a very similar tumor growth suppression phenotype.
It remained plausible that the exosome biogenesis factors were acting cell autonomously to suppress tumor growth, rather than non-autonomously via exosomal PD-L1 to suppress tumor growth via the anti-tumor immune response. To differentiate these alternative possibilities, we next asked whether the effect of Rab27a and/or nSMase2 loss was dependent on an active immune system. WT, Rab27a, nSMase2, and Pd-l1 null TRAMP-C2 cells were injected into NOD-scid IL2rg null (NSG)-immunodeficient mice. In striking contrast to the results seen in immunocompetent mice, the four lines led to end-stage tumors at a similar rate in the immunodeficient background ( Figure 3E ). Therefore, RAB27A and NSMASE2, like PD-L1, promote tumor growth through the suppression of the immune system.
Exosomal PD-L1 Suppresses T Cell Activity in the Draining Lymph Node Next, we asked whether loss of exosomes and PD-L1 have a similar effect on the immune response to the tumor. To address this question, we measured the response in the lymphoid tissues following the injection of WT, Rab27a null, and Pd-l1 null TRAMP-C2 cells ( Figure 4A ). At 14 days, the spleens of mice injected with either mutant cell line were significantly larger than those injected with WT cells ( Figure 4B ). Immunophenotyping of the spleen showed equal percentages of CD8, CD4, and regulatory T cells across the three genotypes ( Figure S6 ). These data are consistent with an enhanced generalized systemic immune response in the absence of exosomes or PD-L1. In contrast, immunophenotyping of the draining lymph nodes showed striking differences between the WT and mutant animals. CD8 positive cells made up a much greater fraction of the T cells following injection of the two mutant tumor cell lines relative to the WT line ( Figure 4C ). The fraction of CD4 was relatively down in the mutants, whereas FoxP3+ T regulatory cells composed a constant fraction of the T cells (Figures 4D and 4E) . Given the relative increase in CD8 cells in the absence of exosomes or PD-L1, we evaluated markers of T cell exhaustion and activation within the CD8 and CD4 T cell populations. The fraction of CD8 and CD4 cells that were PD-1 high were trending down in mice receiving the mutant cells ( Figures 4F and 4G ). Much more significant was a decrease in the percentage of cells expressing the exhaustion marker Tim3 and increase in the percentage of cells expressing the activation marker Granzyme B (Figures 4H-4K ). Furthermore, the fraction of cells positive for the proliferation marker Ki67 was significantly up among the CD8 T cells and trending up among the CD4 T cells ( Figure 4L and 4M). These data are consistent with tumor-derived exosomal PD-L1 traveling to the draining lymph node and suppressing T cell activation.
We hypothesized that if exosomes are acting through PD-L1 to suppress the T cell activation in the lymph node, then in the absence of exosomal PD-L1, immune-competent mice will not only suppress immediate growth of the mutant tumor cells but will also develop memory toward the tumor cells. To test this hypothesis, mice injected with either Rab27a or Pd-l1 null TRAMP-C2 cells on one flank were rechallenged 90 days later with WT TRAMP-C2 cells on the other flank ( Figure 4N ). Age matched mice that had not been previously injected with any tumor cells were used as control. Remarkably, WT TRAMP-C2 tumors failed to grow in any of the mice previously injected with either mutant cell line, but showed normal growth in the age matched controls ( Figure 4O ). Thus, exposure to tumor cells lacking exosomes or PD-L1 results in a robust memory response even against cells that secrete exosomal PD-L1. We interpret this to mean that once the T cells have been exposed to tumor antigens in the absence of exosomal PD-L1, they become resistant to the suppressive effects of exosomal PD-L1.
Exosomal PD-L1 Promotes Growth across Different Tumor Types Next, we asked whether the effect of exosomal PD-L1 on tumor progression is unique to the TRAMP-C2 model. To address this question, we evaluated a colorectal cancer model, MC38. Unlike the TRAMP-C2 model, this model shows a partial response to anti-PD-L1 and therapy (Deng et al., 2014) . Western analysis showed that MC38 cells, like TRAMP-C2 cells, secrete PD-L1 ( Figure 5A ). They also express low levels on the cell surface ( Figure 5B ). Using identical guide RNAs as in the TRAMP-C2 model, Pd-l1 and Rab27a were knocked out in MC38 cells (O) Tumor growth volume over time following secondary subcutaneous injection of 1 3 10 6 WT TRAMP-C2 cells into immunocompetent B6 mice previously sham treated or injected with Pd-l1, Rab27a, or nSMase2 null TRAMP-C2 cells. n = 5 for each condition. Tramp WT versus TRAMP-C2 WT pre-injected with TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 WT pre-injected with TRAMP-C2 Pd-l1 null, p < 0.001. Tramp WT versus TRAMP-C2 WT pre-injected with TRAMP-C2 nSMase2 null, p < 0.001 (two-way ANOVA test). Error bars represent SEM. See also Figure S6. via CRISPR/Cas9-mediated mutagenesis (Figures 5B and S7A) . The Rab27a knockout cells showed a loss of PD-L1 in the secreted fraction, confirming the packaging of PD-L1 in exosomes ( Figure 5A ). Also, similar to TRAMP-C2 cells, the Rab27a and Pd-l1 knockout MC38 cells showed no change in proliferation ( Figures 5C and 5D) . These cells were injected in syngeneic WT mice ( Figures 5E and 5F ). WT MC38 tumors grew rapidly, and mice had to be euthanized starting at 9 days. Loss of either Rab27a or Pd-l1 slowed tumor growth and extended lifespan. However, unlike the TRAMP-C2 model, Pd-l1 loss had a greater effect than Rab27a loss ( Figure 5F ). Therefore, exosomal PD-L1 appears to play an important, but partial role, in this model.
The difference in the effect of Pd-l1 versus Rab27a loss allowed for an epistasis analysis to address the question of whether exosomes are acting specifically through PD-L1 to influence tumor growth. If exosomes have a PD-L1 independent role, their removal should further reduce tumor growth and extend lifespan in the Pd-l1 null background. Therefore, we made Rab27a; Pd-l1 double knockout MC38 cells ( Figure S7 ). These cells grew at a rate similar to that of the Pd-l1 single mutant cells ( Figures 5E and 5F) . Thus, we conclude that exosomes are (D) . n = 10 for each genotype. MC38 WT versus MC38 Rab27a null, p < 0.001. MC38 WT versus MC38 Pd-l1 null, p < 0.001. MC38 WT versus MC38 Pd-l1 null; Rab27a null, p < 0.001 (log rank test). (G) Survival curve for mice injected with WT, Rab27a null, or Pd-l1 null MC38 cells followed by treatment with either anti-PD-L1 or isotype control antibody. n = 5 for each condition. MC38 WT isotype versus MC38 WT anti-PD-L1, p < 0.01. MC38 Rab27a isotype versus MC38 Rab27a anti-PD-L1, p < 0.05. MC38 Pd-l1 isotype versus MC38 Rab27a anti-PD-L1, ns. (log rank test). See also Figure S7. functioning predominantly, if not entirely, through their presentation of PD-L1. The difference in the effect of Pd-l1 versus Rab27a loss on tumor growth also implied that there is an exosome independent pool of PD-L1 that is also functioning to suppress the immune response in this model. We hypothesized that unlike exosomal PD-L1, this pool may be sensitive to anti-PD-L1 antibody. This pool could explain why unlike the TRAMP-C2 model, the MC38 model is partially responsive to anti-PD-L1 antibodies (Deng et al., 2014) . To test this hypothesis, we evaluated the effect on survival of anti-PD-L1 alone and in combination with exosome depletion. Similar to the loss of Rab27a, the treatment of the mice with anti-PD-L1 antibody extended survival, but not to the same degree as loss of Pd-l1 ( Figure 5G) . Remarkably, the combination of Rab27a deletion and treatment with anti-PD-L1 antibodies lead to similar survival curve as the Pd-l1 deletion. This finding strongly supports the conclusion that while exosomal PD-L1 is resistant to anti-PD-L1, there is another pool in A B Figure 6 . Cross-Communication between WT and Mutant TRAMP-C2 Cells at Distant Sites (A) Schematic of the experiment: briefly, immunocompetent B6 mice were co-injected with 1 3 10 6 mutant TRAMP-C2 cells in one flank and with 1 3 10 6 WT TRAMP-C2 cells in the other flank. (B) Tumor growth of WT TRAMP-C2 cells in mice singly injected or co-injected with either Pd-l1 null or Rab27a null cells. n = 5 for each condition. Tramp WT versus TRAMP-C2 WT co-injected with TRAMP-C2 Rab27a null, p < 0.001. Tramp WT versus TRAMP-C2 WT co-injected with TRAMP-C2 Pd-l1 null, p < 0.001. Tramp WT versus TRAMP-C2 WT co-injected with TRAMP-C2 nSMase2 null, p < 0.01 (two-way ANOVA test). Error bars represent SEM. (C) Tumor growth of Pd-l1 null or Rab27a null TRAMP-C2 cells in mice singly injected or co-injected with WT TRAMP-C2 cells. n = 5 for each condition. Error bars represent SEM. (D) Mouse survival curve mice singly injected with WT TRAMP-C2 cells or doubly injected with WT and Pd-l1 null or Rab27a null cells. n = 5 for each genotype. (E) Histological analysis of lymphocyte infiltration of tumors under the noted conditions. Each symbol represents an individual mouse. Representative images for each state (severe, moderate, mild, and none) can be found in Figure S7E. this model, likely cell-surface PD-L1, which is both a significant suppressor of the anti-tumor immune response and sensitive to the antibodies.
D C E
Exosomal PD-L1-Deficient Tumor Cells Can Suppress WT Tumor Growth at a Distance Site Exosomes can enter the blood and lymphatic systems and travel throughout the body, potentially influencing tumor growth at distant sites (Ruivo et al., 2017) . Similarly, immune cells educated at one tumor site can travel throughout the body potentially influencing growth of tumors at distant sites (Chen and Mellman, 2013) . Therefore, we next asked whether the simultaneous injection of WT and mutant cells at different sites would affect growth of either tumor. In particular, could exosomal PD-L1 released from WT tumor cells promote growth of mutant cells at a distant site, and/or could the T cells activated by the mutant cells suppress growth of WT cells at a distant site? To address this question, WT TRAMP-C2 cells were injected in one flank of each mouse simultaneously with Pd-l1, Rab27a, or nSMase2 null TRAMP-C2 cells on the other flank ( Figure 6A ). Tumor growth on each flank was then followed over time. Remarkably, growth of the WT tumor in these double injections was dramatically reduced relative to mice where WT cells alone were injected (Figure 6B) . The effects of Pd-l1, Rab27a, or nSMase2 null cells on the distant WT tumor were similar. In contrast, the WT cells did not have any effect on the growth of Rab27a or nSMase2 null cells Figure 6C ). However, the WT cells did promote the growth of Pd-l1 null cells. This effect was small as tumor growth was much slower than the WT counterparts ( Figure 6C , compare y axis to 6B). The reason for the difference between the Pd-l1 null cells and the exosome-deficient cells is unclear and requires further study. Overall, the double-injected mice had a greatly extended survival relative to those that received WT TRAMP-C2 cells alone ( Figure 6D) . These findings strongly supported the notion that immune cells activated in the draining lymph node of the mutant side were able to travel and attack the WT tumor cells on the opposite flank. Indeed, histological analysis of the WT tumors showed a dramatic increase in the number of infiltrating lymphocytes when co-injected with the mutant cells on the opposite flank ( Figures 6E and S7E ). Together, these data show communication between the tumors, with the effect of the mutant tumor being dominant over that of the WT tumor.
Exogenously Introduced Exosomal PD-L1 Can Rescue Immune Suppression and Tumor Growth
Next, we asked whether exogenously introduced exosomal PD-L1 could suppress the anti-tumor immune response and promote tumor growth. To address the effect on the immune response, we transplanted Rab27a null TRAMP-C2 cells in the flank of syngeneic mice followed by tail vein injections of in vitro collected exosomes from either their WT or Pd-l1 null counterparts ( Figure 7A ). Exosomes from the WT, but not Pd-l1 null, cells were able to induce a systemic immunosuppression as evidenced by nearly a 50% reduction in spleen size (Figure 7B ). Furthermore, the WT exosomes were able to suppress the immune response in the draining lymph node of the Rab27a-deficient cells. Compared to the Pd-l1-deficient exosomes, the WT exosomes led to a reduced CD8/CD4 ratio, while having little effect on the T-reg cells ( Figures 7C-7E ). More importantly, they led to an increase in the fraction of cells expressing high levels of the exhaustion markers PD-1 and TIM3 and low levels of the activation marker Gramzyme B ( Figures  7F-7K ). These findings paralleled the findings seen in mice transplanted with WT versus Rab27a null cells (cf. Figures 4 and 7) . To address the effect on the tumor growth, we transitioned to the MC38 model, given its more rapid growth characteristics. As with the TRAMP-C2 model, Rab27a-deficient MC38 cells were injected in the flank of syngeneic mice followed by exosome injection in the tail vein of the same mice. Consistent with the immune suppression seen in the TRAMP-C2 model, injection of exosomes collected from WT, but not Pd-l1-deficient MC38, cells promoted tumor growth and reduced survival ( Figures 7L  and 7M ). These results confirm that exosomes are functioning through PD-L1 to suppress the anti-tumor immune response and thus promote tumor growth.
DISCUSSION
All together, these data uncover a key role for exosomal PD-L1 in enabling cancer cells to evade anti-tumor immunity. Indeed, in the presence of exosomal PD-L1, T cells in the tumor's draining lymph node express markers of exhaustion and the spleens are smaller. Genetically blocking exosome biogenesis or deleting Pd-l1 reverses the phenotype by strongly promoting T cells activation, proliferation, and killing potential. This effect is reversed again with the introduction of exogenous exosomal PD-L1. Therefore, tumor exosomes have the ability to travel to the draining lymph node, where they present PD-L1 inhibiting T cell activation. Remarkably, blocking the release of exosomal PD-L1 not only suppresses growth of the local tumor cells but also blocks WT tumor cells injected at a distant site either simultaneously or months later. Therefore, enabling T cell activation at the local lymph node leads to a durable systemic immune response that is no longer affected by the secretion of exosomal PD-L1. The end result is extended survival of the afflicted mice.
A role for EVs, including exosomes, in tumor progression has been proposed in a number of settings (Ruivo et al., 2017) . EVs can carry tumor antigens. When taken up by dendritic cells, these antigens can be presented, thereby inducing an immune response (Wolfers et al., 2001) . As such, EVs were originally thought to have an anti-tumor effect. However, more recent studies have suggested a number of immunosuppressive effects. For example, EVs can inhibit dendritic cell maturation, natural killer (NK) cell function, and directly kill CD8 T cells (Abusamra et al., 2005; Liu et al., 2006; Yu et al., 2007) . EVs also have been shown to promote directional migration of tumor cells (Sung et al., 2015) , home tumor cells to lymph nodes (Hood et al., 2011) , induce neovascularization and leakiness of tumor vessels (Peinado et al., 2012; Skog et al., 2008; Zhou et al., 2014) , and, even, establish pre-metastatic niches (Fong et al., 2015; Hoshino et al., 2015) . The mechanisms behind these various functions remain largely speculative.
Here, we present extensive evidence that EVs, specifically exosomes, can function to promote tumor progression by presenting PD-L1. In vitro, exosomes suppressed T cells in a PD-L1-dependent fashion. In vivo, the removal of tumor exosomes from TRAMP-C2 cells using two independent genetic mutations recapitulated the effects of deleting Pd-l1. These recapitulated effects included suppression of tumor growth, increased cellularity of the spleen, and the activation of a T cell response in lymph nodes with similar effects on the various activation, exhaustion, and proliferation markers. All these outcomes were reversed with the injection of in vitro collected exosomes carrying PD-L1. In the absence of PD-L1, the exogenously introduced exosomes had little effect. Therefore, at least in the TRAMP-C2 model, presentation of PD-L1 appears to be the major mechanism by which exosomes promote cancer progression.
This role for exosomal PD-L1 is not limited to the TRAMP-C2 model. Removal of exosomes in the colorectal MC38 model also suppressed tumor growth and extended survival. Once again, the effect was dependent on PD-L1 as the removal of exosomes had no additional effect in the Pd-l1 null background. Interestingly though, unlike the TRAMP-C2 model, the loss of exosomes alone did not have as much of an impact as Pd-l1 loss, suggesting a combined role of exosomal and cellular PD-L1 in the MC38 model. Remarkably, combining exosome loss with anti-PD-L1 treatment extended survival of these mice to a similar degree as removing PD-L1 altogether. These data show that in the MC38 model, both exosomal and cellular PD-L1 play an important role in promoting tumor progression in the latter, but not in the former, being sensitive to anti-PD-L1 therapy. Understanding what regulates the relative surface versus exosomal presentation of PD-L1 will be an important avenue of research going forward.
Several recent papers have identified exosomal PD-L1 in the blood of patients with a variety of cancers including head and neck cancer and melanoma (Chen et al., 2018; Theodoraki et al., 2018) . In melanoma, it has been further shown that patients resistant anti-PD-1 therapy have elevated levels of exosomal PD-L1 in their blood prior to treatment (Chen et al., 2018) . Therefore, our findings on the immunosuppressive and tumor-promoting roles of exosomal PD-L1 are likely to be relevant across many cancer types. However, the degree to which exosomal versus surface PD-L1 is driving immunosuppression will vary between patients and cancer types. Identifying patients who are more or less dependent on exosomal PD-L1 will be critical going forward in deciding those who are more likely to respond to therapy. Measuring levels in the blood as shown in these recent studies is likely to be one such strategy.
Going forward, targeting both cell-surface and exosome presentation of PD-L1 should be considered in any therapeutic strategy. The TRAMP-C2 model is resistant to current anti-PD-L1 antibody blockade (Yu et al., 2012) . However, the deletion of Pd-l1 in the tumor cells had a striking effect. Similarly, although the MC38 model shows partial responsiveness to anti-PD-L1 therapy (Deng et al., 2014) , deletion of the Pd-l1 gene has a greater effect ( Figure 5) . These data are all consistent with exosomal PD-L1 being resistant to current anti-PD-L1 therapy. The reason exosomal PD-L1 is resistant is unclear. It is possible that how PD-L1 is presented on the exosome makes it less responsive to the current antibodies. Alternatively, exosomal PD-L1 may be produced at high enough levels that it can compete with the delivered antibody. It is also possible that exosomes can reach targets that are sequestered from the effects of the antibody. It will be important to tease apart the interactions of exosomal PD-L1 with current therapeutics.
Potentially the most promising therapeutic implication of our findings is that inhibition of exosome secretion at one tumor site can lead to a systemic and durable immune response against distant tumor sites or secondary tumor challenges. This observation is reminiscent of the abscopal effect, originally seen in patients treated with irradiation (Ngwa et al., 2018) . In particular, irradiation of the primary tumor can lead to secondary regression of metastases. It is thought that this phenomenon is driven by activation of anti-tumor immune response and preclinical studies combining irradiation with immunosuppression are underway (Ngwa et al., 2018) . It will be interesting to determine whether localized anti-exosomal therapy combined with systemic anti-PD-L1 blockade could synergize to induce a systemic immune response against multiple tumor sites simultaneously.
Here, we used genetics to dissect the role of exosomal PD-L1 in tumor progression by deleting two important exosomal biogenesis genes: Rab27a and nSMNase2. The deletion of Rab27a led to loss of all exosomes as measured by markers (CD63, HRS), particle tracking, and electron microscopy. The deletion of nSMNase2 led to a loss of a majority, but not all, exosomes, as measured by the same assays. Therefore, both enzymes represent potential therapeutic targets. Small molecule inhibitors toward NSMNASE2 and RAB27A already exist, GW4869 and Nexinhib-20, respectively (Johnson et al., 2016; Luberto et al., 2002) . However, these small molecules are unable to inhibit exosome release in multiple cancer cell lines, including PC3, or show an in vivo effect in the MC38 model (Phuyal et al., 2014) (Figures S7D-S7H ), even though their respective knockouts had a profound effect (this paper). Therefore, there is a need for more effective small molecules toward these targets before any hope of developing them into drugs. Based on our findings, such drugs could have the potential to act alone or in combination with current immune-checkpoint therapies, reaching a large population of cancer patients.
In summary, we have discovered that exosomal PD-L1 is a major regulator of tumor progression through its ability to suppress T cell activation in draining lymph nodes and that its inhibition can lead to a long-lasting, systemic anti-tumor immunity.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: 
ACKNOWLEDGMENTS
This publication is part of the NIH Extracellular RNA Communication Consortium paper package and was supported by the NIH Common Fund's exRNA Communication Program. We thank Mark Ansel, Andrei Goga, Bo Huang, Noelle L'Etoile, and Robert Raffai for helpful discussions throughout development of this project. We thank Jason Cyster for helpful feedback on the manuscript. We thank Adam Olshen for helpful advice on the statistical tests. We thank Atsushi Urano and Matthias Hebrok for the CD63-GFP construct. This work was funded by the NIH Common Fund Extracellular RNA Consortium (U19 CA179512), the George and Judy Marcus Innovation Fund, and NIH training grant (F31CA200163) (to T.H.).
AUTHOR CONTRIBUTIONS
M.P. contributed to Figures 1A, 2B -2D, 2G, 2H, 3-7, S1A, S1B, S2, S3A-S3E, S3G, S4F-S4H, and S5-S7. T.H. contributed to Figures 1, 2E , 2F, 2H, S1, and S4. 7, and S6. B.C. contributed to Figures 1, 4, 7, S1A, S1B, S2, and S4C. C.D.B. contributed (Hui et al., 2017) . All cells were cultured at 37 C in a humidified atmosphere containing 5% CO2.
Mouse tumor cell lines TRAMP-C2 cells were obtained from ATCC, where they had been authenticated, TRAMP-C2 cells were derived from a primary large T antigen expressing tumor that developed in a C57BL/6 male mouse (Foster et al., 1997 . MC38 cells are a colon cancer cell line derived from a female C57BL/6. All cells were cultured at 37 C in a humidified atmosphere containing 5% CO2.
Mice C57BL/6J (stock # 000664) mice were purchased from ''The Jackson Laboratory'' and/or bred in the UCSF animal house. Immunodeficient mice NOD-Prkdc em26Cd52 Il2rg em26Cd22 /NjuCrl (catalog # 24110022) were obtained from Charles River. Only male mice (approximately 8-10 weeks old unless otherwise specified in text) were used for all experiments. Mice were kept under the preapproved guidelines of the Institutional Animal Care and Use Committee at UCSF. Mice were housed in pathogen free conditions. Mice dying for nonrelated cancer causes were excluded from the studies (i.e., fights or infections). Additional information (i.e., sample size, replicates) is described in the figure legends. Each experimental group was created with mice derived from different brood.
METHOD DETAILS
Cell lines treatments
To inhibit lysosome function, cells were cultured with 250 nM BafA1 (Cell Signaling, cat. 54645S) for six hours. To inhibit proteasome function, cells were cultured in 10 uM of MG132 (SIGMA, cat, M7449) for six hours.
To investigate PD-L1 glycosylation, PC3 cell lysate were treated with PNGase F (Sigma-Aldrich, cat. P7367). To investigate further glycosyl modification in the Golgi apparatus, PC3 cell lysate were treated with Endo H (NEB, cat. P0702S).
For IFN-g treatments, 10ng/mL IFN-g (PeproTech -human cells, cat. 300-02) (Abcam -mouse cells, cat. Ab9922) to media for 48 hours prior to exosome and cell collections.
For GW4869 treatments, 10mM GW4869 (Sigma-Aldrich, cat. D1692) to media for 48 hours prior media collections.
Exosome/Secreted Vesicle isolation PC3 and SK-Mel-28 cells were plated at a density of 5 million per 15 cm plate (Corning 430599), cultured for 48 hours and media from six plates were pooled. For TRAMP-C2 and MC38 secreted vesicle extractions, cells were plated at a density of 3 million per 15 cm plate for 48 hours and media from 6 plates were pooled.
For vesicle enrichment, media was centrifuged at 300 g for 10 minutes at room temperature, followed by 2k g for 20 min at 4 C then 12k g for 40 minutes at 4 C. Supernatant was then centrifuged twice at 100k g, for 1 hour then 10 minutes at 4 C. For exosome purification, the 100k g pellet was further spun on a sucrose gradient (20%-60% sucrose) for 16 hours at 4 C at 100k g. Fractions were collected and sucrose concentration measured using a refractometer.
It was noted that components of FBS lacked any reactivity to anti-human or anti-mouse PD-L1 and thus in experiments where only proteins were measured, vesicles were collected directly from culture media described above. In experiments where vesicles or exosomes would be counted or visualized, FBS was replaced by Knock-out Serum Replacement (KSR, GIBCO 10828028) to exclude particles present in the FBS. 
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